
In this episode, Ian Wood discusses how to prevent muscle loss associated with GLP-1 weight loss medications and emphasizes fundamental health practices.
Apply for coaching 👉🏻 https://www.coachianwood.com/ A new drug called apitegromab has been developed to prevent muscle loss in people taking GLP-1 weight loss medications like Ozempic and Mounjaro — and a study published in Nature Medicine suggests it works. People taking it alongside tirzepatide lost around 15% of their weight from muscle, compared to 30% in those who didn't take it. But in this episode, I want to have a different conversation. Because the muscle loss being caused by these medications isn't a mystery. Large, aggressive calorie deficits — created by any means, including GLP-1 drugs — break down muscle tissue alongside fat. And we already know how to prevent most of that: a moderate calorie deficit, adequate protein intake, and consistent resistance training. These aren't complicated interventions. They're the same fundamentals that would get most slightly overweight, otherwise healthy people the result they want — without the medication, without the side effects, and without the need for a second drug to manage the first one. In this episode I break down what the EMBRAZE trial actually found, why the muscle loss is happening mechanically, what the evidence says…
Host: Ian Wood
Organizations: Nature Medicine
Products: Ozempic, Mounjaro, apitegromab
Explore listener stats, chart rankings, contacts and more on the The Forever Athletic Podcast podcast page.